Ekaterina Poliakova-georgan

Array ( [id] => 18241969 [patent_doc_number] => 20230074280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS [patent_app_type] => utility [patent_app_number] => 17/821693 [patent_app_country] => US [patent_app_date] => 2022-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83154 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451475 [patent_doc_number] => 20230192753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 17/818858 [patent_app_country] => US [patent_app_date] => 2022-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14037 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18295292 [patent_doc_number] => 20230104978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => RNA-Editing Oligonucleotides and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/817874 [patent_app_country] => US [patent_app_date] => 2022-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817874 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436391 [patent_doc_number] => 20230183685 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => SYNTHETIC TRANSFER RNA WITH EXTENDED ANTICODON LOOP [patent_app_type] => utility [patent_app_number] => 17/876803 [patent_app_country] => US [patent_app_date] => 2022-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10270 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17876803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18212600 [patent_doc_number] => 20230058864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING PATHOLOGIC CALCIFICATION [patent_app_type] => utility [patent_app_number] => 17/814968 [patent_app_country] => US [patent_app_date] => 2022-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22358 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814968 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19731251 [patent_doc_number] => 12209242 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-28 [patent_title] => siRNA based on RNA sequence of SARS-CoV-2 and use thereof [patent_app_type] => utility [patent_app_number] => 17/811961 [patent_app_country] => US [patent_app_date] => 2022-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 8160 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811961 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18147727 [patent_doc_number] => 20230021584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => Methods Of Treating Decreased Bone Mineral Density With Kringle Containing Transmembrane Protein 1 (KREMEN1) Inhibitors [patent_app_type] => utility [patent_app_number] => 17/855053 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17855053 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18058342 [patent_doc_number] => 20220389428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => NUCLEIC ACID, COMPOSITION AND CONJUGATE COMPRISING THE SAME, AND PREPARATION METHOD AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/852888 [patent_app_country] => US [patent_app_date] => 2022-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42617 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 193 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17852888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18910521 [patent_doc_number] => 11873492 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-16 [patent_title] => Medication and diagnostic kit for inhibiting metastasis and invasion of breast cancer, shRNA molecule for silencing expression of human LINC01614 and application thereof [patent_app_type] => utility [patent_app_number] => 17/852380 [patent_app_country] => US [patent_app_date] => 2022-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 3330 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17852380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511673 [patent_doc_number] => 20230227855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => Materials and Methods for Treatment of Myotonic Dystrophy Type 1 (DM) and Other Related Disorders [patent_app_type] => utility [patent_app_number] => 17/851227 [patent_app_country] => US [patent_app_date] => 2022-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17851227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20372696 [patent_doc_number] => 12480122 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => Inhibition of polyomavirus replication [patent_app_type] => utility [patent_app_number] => 17/846457 [patent_app_country] => US [patent_app_date] => 2022-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 53 [patent_no_of_words] => 17339 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19449254 [patent_doc_number] => 20240309384 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => INVERTED CHIMERIC siRNA MOLECULES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/571985 [patent_app_country] => US [patent_app_date] => 2022-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24360 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18571985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18320010 [patent_doc_number] => 20230118138 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => USE OF SCAMP3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 17/845178 [patent_app_country] => US [patent_app_date] => 2022-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17845178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265700 [patent_doc_number] => 20240209399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => SYSTEMS, METHODS, AND COMPONENTS FOR RNA-GUIDED EFFECTOR RECRUITMENT [patent_app_type] => utility [patent_app_number] => 18/570914 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22493 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -69 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18570914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18321232 [patent_doc_number] => 20230119360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => PHARMACEUTICAL COMBINATION OF A THERAPEUTIC OLIGONUCLEOTIDE TARGETING HBV AND A TLR7 AGONIST FOR TREATMENT OF HBV [patent_app_type] => utility [patent_app_number] => 17/843740 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54750 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18854095 [patent_doc_number] => 11851658 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-26 [patent_title] => Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA [patent_app_type] => utility [patent_app_number] => 17/836789 [patent_app_country] => US [patent_app_date] => 2022-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 74030 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18312804 [patent_doc_number] => 20230116704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES [patent_app_type] => utility [patent_app_number] => 17/832182 [patent_app_country] => US [patent_app_date] => 2022-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 115693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17832182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19361125 [patent_doc_number] => 20240263159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => GENE EDITING IN PRIMARY IMMUNE CELLS USING CELL PENETRATING CRISPR-CAS SYSTEM [patent_app_type] => utility [patent_app_number] => 18/566410 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24697 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18566410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18108017 [patent_doc_number] => 20230000897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => Treatment Of Cerebrovascular Disease With Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) Agents [patent_app_type] => utility [patent_app_number] => 17/829801 [patent_app_country] => US [patent_app_date] => 2022-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27485 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17829801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19104633 [patent_doc_number] => 11957706 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Composition for preventing or treating fibrosis including an inhibitor of CDK17 expression or activity [patent_app_type] => utility [patent_app_number] => 17/828351 [patent_app_country] => US [patent_app_date] => 2022-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 12 [patent_no_of_words] => 7086 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17828351 [rel_patent_id] =>[rel_patent_doc_number] =>)